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r Thoralf M. Sundt (Rochester, Minn). Well done, Dr Chang. A
ery nicely presented article. My colleagues and I from the other
linic share your concern about both the short- and long-term
utcomes of these patients. We are seeing more and more of these
olks, and it is really a tough population with which to deal. If I
nderstand your data correctly, given the choice from the menu of
adiation-treated patients on whom to operate, I should pick the
angential ones and leave the extensive ones to my junior col-
eagues. Unfortunately, most of the time, we have to deal with the
ases that we are served up, and accordingly, I have some specific
uestions for you that are perhaps more relevant as we face patient
y patient in the clinic.
With regard to the individuals having tangential radiation, you
entioned some of this in your article, which I appreciate you
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CDending to me. Could you comment on the use of the ITA ipsilat-
ral to the radiation? I have quite frankly not used the ITA on the
ide of the radiation; this is almost an absolute rule for me. That is
robably the only population in which I do not use the ITA to the
eft anterior descending coronary artery, and I would like your
omments. What is your practice, and do you have any data about
ate ITA patency if the ITA has been irradiated?
A second question, focusing more on the patients receiving
xtensive radiation, who are the more problematic, you present
omething of a paradox. You argue for a definitive operation and
agree with that, the redo—as miserable as the first operation
s—the redo is really, really tough, and yet ischemic time was one
f the risk factors, so how do you balance that? What are your
ndications, for example? How much aortic regurgitation will you
olerate? When is the aortic regurgitation enough to warrant pro-
onging the ischemic time to subject the patient to an aortic valve
eplacement, which incidentally is a nontrivial exercise in these
atients?
How do you handle the mitral valve in these patients? Repair
ersus replacement—it can be a problem if they leak after a repair
nd you are faced with the challenge of whether to do a rerepair or
erform a transplantation. Pericardiectomy— how often did these
atients undergo pericardiectomy, and do you ever do a pro-
hylactic pericardiectomy? That is a frequent problem in these
adiation-treated patients.
Finally, with regard to your suggestion about transplantation,
hese patients are very tough as redos on the transplant list as well,
nd I wonder what guidelines you currently use to triage them up
ront. It seems we have an attitude today to give everybody a shot
ith a conventional operation and if that fails to refer them on to
ransplantation. As one of the transplant surgeons at my institution,
am a little bit more circumspect about that. The redo is really
npleasant for these.
Thank you very much, and I thank the association for the
pportunity to open the discussion on this article.
Dr Chang. Thank you, Dr. Sundt, for your comments and
uestions. In terms of internal thoracic artery use, we found that it
as used surprisingly less often than our normal coronary revas-
ularization practice pattern. In fact, barely half the eligible pa-
ients received an internal thoracic artery graft. We do no think
angential breast radiation precludes use of the internal thoracic
rtery. Studies from other institutions have shown conflicting
esults. Some authors state that despite radiation, the ipsilateral
nternal thoracic artery can be used, whereas others state that it
annot.
In terms of late patency, we have few angiographic studies, in
ommon with everybody else.
For the extensive patients, one must balance longer myocardial
schemic times against definitive operations. What we try to do is
im for a definitive operation. If the valve can be easily repaired,
e repair it. If there is any doubt, we believe replacement is the
est option. Thus, for example, we believe that a rapid definitive
peration is better than multiple pump runs in order to try to
alvage a leaking valve. Whether or not the longer myocardial
schemic time can be balanced out by the one-time definitive
peration has not yet been clarified.
Pericardectomy was performed in only 6 patients. Pericarditis
as present in less than 10% of patients. Thus, we do not perform p
12 The Journal of Thoracic and Cardiovascular Surgery ● Febrrophylactic pericardectomy. This does not seem to have been a
roblem, but it warrants careful follow-up.
In terms of transplantation, this was an issue brought up by Dr.
ytle recently. Although we usually try to give everyone a shot at
onventional surgery, we have been wondering if heart or heart–
ung transplantation might be better to avoid redo operations.
hese patients have already had radiation. They have had their
issue planes obliterated, and their tissues are not normal. Trying to
o an anastomosis, especially a bronchial or tracheal anastomosis,
n this radiated field can be challanging. Performing a redo oper-
tion on top of that would certainly make it a high-risk procedure.
e have not extended our practice pattern to going straight to
ransplantation, but it is something we are considering.
Currently, our indications for surgery are essentially the same
s for nonirradiated patients, although we prefer patients who are
ore symptomatic; we do not just look at their physiologic ab-
ormalities.
Dr James Mark (Stanford, Calif). Well done. Nice presenta-
ion. Dr Chang has brought an important problem to our attention
nd that is the aftermath of radiation to the chest. The patients to
hom he refers must have had chemotherapy as well, at least some
f them, and that treatment modality has its own problems. A few
eeks ago, Dr Saul Rosenberg, a senior medical oncologist at
tanford—that means he is as old as I am—gave a medical grand
ounds in which he reviewed the 45-year experience of the treat-
ent of Hodgkin disease at Stanford using first radiotherapy alone
nd then radiotherapy combined with chemotherapy. Their group,
pearheaded originally by Dr Henry Kaplan, who introduced the
inear accelerator into clinical use, has been religious in their
dherence to clinical trials and have found that by judicious
weaking of radiotherapy ports and dosages and by changing
hemotherapy combinations to include smaller doses of more
rugs, they can maintain a high tumor control rate while minimiz-
ng the side effects. For example, the present chemotherapy regi-
en includes small doses of 7 drugs in the treatment of Hodgkin
isease. Mediastinal complications such as we have heard about
oday are not the only deleterious effects of radiotherapy. We have
ll seen malignant tumors of the chest wall in radiated fields, and
he side effects of chemotherapy are too numerous and too diffuse
o even talk about today. Dr Chang tells us about a relatively short
ollow-up period, 2 years plus, in these patients. I know that the
leveland Clinic group will remain vigilant in looking for addi-
ional problems as time goes on. Some years ago, we reported an
ncrease in postoperative cardiac problems in patients who under-
ent preoperative radiation for lung cancer. Has Dr Chang studied
his group at all?
Thank you very much.
Dr Chang. Thank you, Dr. Mark. Stanford has been one of the
eaders in the treatment of Hodgkin disease. In our conclusions, we
lso have recognized that it is important to pay careful attention to
hat radiation fields have been used as well as what chemotherapy
reatments were given, as cancer treatments are constantly evolv-
ng. Over the last 20 years, treatment of Hodgkin disease, as Dr.
ark pointed out, has changed. It used to entail larger radiation
elds, but now involves less radiation and more chemotherapy.
ost of the patients in our study were treated about 20 years ago.
owever, 20 years from now or even 10 years from now, patients
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CDor Hodgkin disease will be different, and their extent of radiation
ay be different as well.
We do not have specific information on chemotherapy. We
now that about two-thirds to three-quarters of the patients did
ave chemotherapy, but because most were treated at outside
nstitutions, we did not have specific data.
We did not look specifically at lung cancer as a subgroup,
ecause only 15 patients had it. Rather, they were investigated in
he variable radiation group.
Dr Donald Low (Seattle, Wash). Dr. Chang, very good article.
learly the extensive and variable groups are at greatest risk for
omplications and outcomes, which are worse than seen in the
eneral population. With the experience you have just had, do you
hink the tangential radiation group is at any substantial increased
isk for complications, or is their risk equivalent to that of the
eneral population?
Dr Chang. That is a good point and one we were trying to
mphasize: Cardiac disease in the tangential group is most likely
elated to the natural history of conventional heart disease rather
han to the radiation itself. Those patients more closely match the
eneral population and probably should not be considered “radi-
tion heart disease” patients. They do have some changes in
ulmonary function, probably making them a slightly worse risk
han nonirradiated patients, because the lung is partially involved
n tangential radiation. These patients do have some pathologic t
The Journal of Thoracichanges in their lungs, but certainly minor compared with the two
ther groups.
Dr D. Craig Miller (Stanford, Calif). Nice work. I was
weaked by Dr Sundt’s question and heard your response that you
o not think much of parietal pericardiectomy the first time around
f you are going to embark on a conventional cardiac operation for
he extensive group. I share your group’s reticence and maybe we
re not doing the right thing here. We are kidding ourselves and
aybe transplantation in the suitable candidates—not all these
eople are with the radiation fibrosis to the lung and the esophagus
nd what not—but we have something that Stanford calls “Stin-
on’s rule,” which is probably not published, but it has been
round for 30 years. In this extensive group, with which we have
ll too much experience, Ed pointed out early, 20 or 25 years ago,
hat even though the parietal pericardium might look normal, it
robably is very wise to do a phrenic to phrenic pericardiectomy
nteriorly, at least the first time you are there, for left main disease
r AVR or mitral or whatever because these people come back and
aunt you badly. That is if you are going to embark on a conven-
ional cardiac operation as a first shot, which is getting less and less
ttractive.
Dr Chang. Thank you for your comment. That may be the best
ay to go, but our experience with pericardectomy in general
uggests that post-radiation patients account for less than 10% of
hat population.
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